Tofacitinib Citrate (CP-690550 citrate): Selective JAK3 Inhibitor Data

Executive Summary:
Tofacitinib citrate (CP-690550 citrate) is a potent and selective JAK3 inhibitor, showing an IC50 of approximately 1 nM against JAK3, with 20-fold and 100-fold lower potency for JAK2 and JAK1, respectively (APExBIO product information). It effectively suppresses cytokine-driven lymphocyte proliferation and modulates Th1, Th2, and Th17 differentiation (review). In endothelial cell models, tofacitinib reduces inflammatory adhesion molecule expression at 1 μM but may enhance procoagulant markers at higher concentrations (ACR Open Rheumatology). The compound is used at 10–100 nM in most in vitro protocols, with reliable solubility in DMSO and water under specified conditions (APExBIO). Its use is foundational for dissecting JAK-STAT signaling and modeling inflammatory diseases (Houston Biochem).

Biological Rationale

Janus kinases (JAKs) are non-receptor tyrosine kinases essential for cytokine signal transduction, particularly in immune cells. JAK3, predominantly expressed in hematopoietic tissues, is integral for the signaling of the common gamma-chain (γc) cytokine family, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Dysregulation of JAK-STAT pathways contributes to autoimmune and inflammatory disorders, making JAK3 a critical target for immune regulation research. Tofacitinib citrate, a selective JAK3 inhibitor, allows precise manipulation of these pathways to study lymphocyte proliferation inhibition and cytokine modulation (Tofacitinib.biz). This article extends prior reviews by integrating recent cardiovascular safety and endothelial cell data, clarifying mechanistic boundaries in immune research.

Mechanism of Action of Tofacitinib citrate (CP-690550 citrate)

Tofacitinib citrate targets the ATP-binding site of JAK3, resulting in potent inhibition with an IC50 of approximately 1 nM. Its selectivity is evidenced by a 20-fold and 100-fold decrease in potency for JAK2 and JAK1, respectively. Reported Ki values are 6.5 nM for JAK3, 21.7 nM for JAK2, and 1.6 nM for JAK1 (APExBIO). Inhibition of JAK3 blocks cytokine-driven STAT phosphorylation, subsequently reducing lymphocyte activation, proliferation, and differentiation. Under Th1 and Th2 polarization conditions, tofacitinib suppresses IFN-γ and IL-4 production, respectively, and modulates IL-17, Foxp3, and IL-10 expression in Th17 differentiation models (Gap-27.com). This mechanism positions it as a precision tool for immune modulation assays and autoimmune disease model systems, as detailed in the Houston Biochem protocol guide.

Evidence & Benchmarks

• Tofacitinib citrate demonstrates an IC50 of ~1 nM for JAK3 inhibition, with 20- and 100-fold reduced potency for JAK2 and JAK1, respectively (APExBIO).
• In human endothelial cells, 1 μM tofacitinib reduces induction of ICAM-1 and E-selectin in the presence of TNF and IL-17A, but at 10 μM may enhance VCAM-1 and ICAM-1 expression (Zavoriti & Miossec 2025).
• Tofacitinib suppresses IFN-γ (Th1) and IL-4 (Th2) cytokine production during differentiation, and modulates IL-17, Foxp3, and IL-10 under Th17 conditions (mechanism review).
• Solubility is ≥25.22 mg/mL in DMSO and ≥3.4 mg/mL in water (with warming/ultrasound); insoluble in ethanol (APExBIO).
• Effective in vitro concentrations typically range from 10 nM to 100 nM for immune cell assays (FluoresceinTSA workflow).

Applications, Limits & Misconceptions

Tofacitinib citrate is widely used for dissecting JAK-STAT signaling in immune cell models, including studies on lymphocyte proliferation inhibition, cytokine signaling, and differentiation of Th1, Th2, Th17, and regulatory T cells (Gap-27.com). Its reproducibility and selectivity facilitate benchmarking in inflammatory disorder research. The compound is routinely employed in autoimmune disease model systems to parse cytokine-specific signaling effects. However, its activity profile is concentration-dependent: while nanomolar doses yield selective JAK3 inhibition, micromolar concentrations may broaden target coverage and induce off-target effects. In endothelial cells, for example, higher doses can paradoxically enhance procoagulant markers or adhesion molecules in the context of inflammatory cytokine challenge (Zavoriti & Miossec 2025).

Common Pitfalls or Misconceptions

• Assuming JAK3 selectivity at micromolar concentrations—off-target inhibition of JAK1/JAK2 occurs above 100 nM.
• Using ethanol as a solvent—Tofacitinib citrate is insoluble in ethanol and should be dissolved in DMSO or water with warming.
• Expecting direct inhibition of TNF or IL-17A signaling—JAK-STAT is not the primary pathway for these cytokines.
• Assuming cardiovascular safety at high concentrations—procoagulant markers may be upregulated in endothelial models above 1 μM.
• Prolonged storage of stock solutions at room temperature—compound stability is optimal at -20°C.

Workflow Integration & Parameters

• Stock Solution Preparation: Dissolve at ≥25.22 mg/mL in DMSO; for aqueous stocks, use ≥3.4 mg/mL with gentle warming and ultrasound (APExBIO).
• Experimental Concentration: Use 10–100 nM for immune cell assays to ensure JAK3 selectivity (FluoresceinTSA).
• Storage: Store solid material and DMSO stocks at -20°C; avoid long-term storage of diluted solutions.
• Assay Timing: Add tofacitinib 0.5–1 hour before cytokine stimulation in signal transduction studies.
• Solvent Control: Use matched DMSO or water controls for all treatment groups.

Conclusion & Outlook

Tofacitinib citrate (CP-690550 citrate) from APExBIO remains a critical reagent for immune regulation and inflammatory disorder research, enabling precise JAK-STAT pathway modulation at nanomolar concentrations. It provides reproducible benchmarks for lymphocyte signaling assays and disease modeling. Recent endothelial cell studies underscore the importance of dose selection, as excessive concentrations may induce off-target effects or alter cardiovascular markers. Cross-referencing these mechanistic data with established immune models helps clarify appropriate applications and boundaries for experimental design. For deeper workflow guidance, see the Houston Biochem guide, which this article extends by integrating cardiovascular and cytokine-specific data. For a systematic comparison of vascular effects, the STAT5.com review offers additional context.